Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses findings from a biomarker analysis of patients with metastatic mismatch repair proficient (pMMR) colorectal cancer (CRC) receiving regorafenib and nivolumab. Tissue samples were subjected to the Xerna TME Panel, and potential predicative biomarkers were assessed. Whilst KRAS and PD-L1 did not determine treatment outcomes, low Treg in the tumor microenvironment was associated with longer progression-free survival (PFS). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ